Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation
A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 1287 participants.
Also called NCT04755283
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose supportive care
- Phase
- Phase 2
- Enrolled
- 1,287 participants
- Registry
-
NCT04755283 -
2020-004507-13
-
- Main results
- Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation
- Other papers using this trial's data
- Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial
- Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation: A Prespecified Analysis of the Phase 2b AZALEA-TIMI 71 Trial
- Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in the AZALEA-TIMI 71 study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Results first posted
- Countries
- United States, Canada, Czechia, Hungary, Poland, South Korea, Taiwan
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT04755283. Randomized; triple masking; primary purpose supportive care. Start 2021-02-02 (actual); primary completion 2024-02-15 (actual). Results posted on 2025-07-30.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation
- Acronym
- AZALEA-TIMI 71
- Condition
- Atrial Fibrillation (AF)
- Condition
- Stroke
- Intervention (Biological)
- Abelacimab
- Intervention (Drug)
- Rivaroxaban
- Lead sponsor
- Anthos Therapeutics, Inc.
- Collaborator
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct04755283- Content hash
c24778faeacf370f80a7fe12a1fcf857be93a94b7548347b8078142ce71f422e